Crystagen
Tissue experiments · No established human dosing schedule
Crystagen is the EDP tripeptide examined in immune-tissue models. A clinically supported human dosing schedule is missing. Tissue experiments · No established human dosing schedule.
Reviewed 2026-10-17. A source reference, not a personal treatment plan. Discuss treatment decisions with a qualified clinician.
Dose reference
| STUDY CONTEXT | Dose | Frequency | Context |
|---|---|---|---|
| Human dosing | Not established | No validated schedule | A tissue response does not define an effective or safe human dose. Amounts claimed in patents require separate clinical confirmation. Source |
A tissue response does not define an effective or safe human dose. Amounts claimed in patents require separate clinical confirmation.
Source context
The cited spleen study examines immune-cell effects during ageing. Its abstract describes B-cell activation, which is an experimental observation rather than evidence of clinical immune restoration.
Reading the dose correctly
A tissue response does not define an effective or safe human dose. Amounts claimed in patents require separate clinical confirmation.
Download the chart
Further reading
Crystagen monograph on myPeptides
References
Why is there no numerical dose for Crystagen on this card?
A tissue response does not define an effective or safe human dose. Amounts claimed in patents require separate clinical confirmation.
Does a missing dose mean that no research exists?
This card describes tissue experiments. Evidence of a mechanism, a laboratory finding or an exposure does not by itself establish a useful and safe human treatment schedule. The monograph explains the distinction.